`NEW YORK (Reuters Health) Jun 14 – In a dose-finding trial, a combination of the oral cytotoxic agent temozolomide plus the cytostatic agent thalidomide demonstrated good tolerability and antitumor activity in patients with advanced melanoma.
As reported in the June 1st issue of the Journal of Clinical Oncology, Dr. Wen-Jen Hwu and colleagues from Memorial Sloan-Kettering Cancer Center in New York assigned 12 patients with unresectable stage III or IV melanoma without brain metastases to one of four treatment groups.
The three patients in level 1 received 6 weeks of treatment with temozolomide 50 mg/m per day. This was followed by a 4-week break. The remaining three treatment levels included 6 weeks of temozolomide 75 mg/m per day plus thalidomide, which was followed by a 4-, 3- or 2-week break. The researchers started thalidomide at a dose of 200 mg/day, which they increased in 100-mg increments to a maximum of 400 mg/day.
האם המהפכה הטיפולית בהשמנת יתר תפרוץ את חומת הכלכלה? פרופ' רז ופרופ' שטרן
לפניכם הרצאה ודיון שהתקיים בין פרופ’ איתמר רז ופרופ’ נפתלי שטרן בנושא השפעות החידושים הטיפוליים בתחום ההשמנה.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!